New drug combination for advanced prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This study tests a new drug (pocenbrodib) alone or combined with another hormone therapy (darolutamide) for men with advanced prostate cancer that has spread. It is for those who have already tried Pluvicto and one other hormone therapy, but not yet chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a confirmed diagnosis of prostate adenocarcinoma (a common type of prostate cancer).
- Your cancer has spread to other parts of your body (seen on a scan within the last 56 days).
- For the main part of the study: you have already had at least 2 cycles of Pluvicto and one type of previous hormone therapy, but no chemotherapy for your current advanced prostate cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding the investigational drug mevrometostat to the standard treatment enzalutamide works better than enzalutamide alone for men with prostate cancer that has spread to other parts of the body (metastatic castration-sensitive prostate cancer). You may benefit if you haven't yet received chemotherapy or similar strong treatments for this stage of cancer.
This study tests several new drug combinations for men with advanced prostate cancer that has spread and stopped responding to standard hormone treatments. It aims to find better ways to control the disease and improve outcomes.
This trial is testing a new combination therapy for men with advanced prostate cancer that has stopped responding to hormone treatment. The goal is to see if this treatment can shrink tumors or slow down the cancer, and it may offer a new option when standard treatments have not worked.
This trial tests a combination of two oral medications (darxiciclib and abiraterone) for men with advanced prostate cancer that has spread and no longer responds to standard hormone therapy. It may help if you have already tried one newer hormone therapy and are looking for another option.
This trial tests a new drug called dalpiciclib combined with standard hormone therapy (abiraterone and prednisone) for men with prostate cancer that has spread and is hormone-sensitive. The goal is to see if adding the new drug helps control the cancer better than the standard treatment alone.
This trial tests two new drugs (QLC5508 and QLH12016) alone or together with other treatments for prostate cancer that has spread to other parts of the body. It may be an option if standard treatments have stopped working or caused side effects.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.